Quince Therapeutics, Inc. (QNCX) Form 8-K — Oct 6, 2026
Quince Therapeutics stockholders approved a special-meeting slate on October 6, 2026, including the issuance of common stock upon conversion of Series C Non-Voting Convertible Preferred Stock tied to Orphai Therapeutics — an issuance representing more than 20% of shares outstanding that may, with board and management changes, result in a change of control. Stockholders also approved increasing authorized common stock from 250,000,000 to 275,000,000 shares, plus the 2026 Equity Incentive Plan (821,872 initial shares plus up to 1,377,845 returning shares and 5% annual evergreen) and a 2026 ESPP with a 142,045-share initial reserve.
Key figures
- Shares Outstanding
- 1017063
- Iso limit
- 7,000,000 shares
- Percent present
- 60%
- Plan share reserve
- 821,872 shares plus up to 1,377,845 returning shares
- Espp initial reserve
- 142,045 shares
- Authorized shares after
- 275,000,000
- Authorized shares before
- 250,000,000
- Prior reverse split ratio
- 1:20 (effective June 29, 2026)
- Shares present at meeting
- 611465
- Broker non votes proposal 1
- 261531
- Total authorized after amendment
- 285,000,000 (incl. 10,000,000 preferred)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.